Antiviral prophylactic intervention for hepatitis C virus in patients undergoing liver transplantatio

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Gurusamy, Kurinchi Selvan ^a   Samraj, K ^b   Davidson, B R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; OKT 3; STEROID;

CLINICAL PROTOCOL; CLINICAL TRIAL; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NONHUMAN; POSTOPERATIVE COMPLICATION; RANDOMIZATION; REINFECTION; REVIEW; RISK BENEFIT ANALYSIS;

EID: 44949255521     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006573     Document Type: Review

References (32)

1. Belli 2001 Belli LS, Alberti AB, Rondinara GF, de Carlis L, Corti A, Mazza E, et al. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial. Transplantation Proceedings 2001;33(1-2):1353-4.
2. Berenguer 2003 Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38(1):34-41.
3. Bombuy 2004 Bombuy E, Fondevila C, Rodriguez-Laiz G, Ferrer J, Amador A, Valentini M, et al. Ischemic preconditioning in adult living donor liver transplantation, a pilot study [EASL abstract]. Journal of Hepatology 2004;40(Supplement 1):39.
4. Cameron 2006 Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Annals of Surgery 2006;244(4):563-71.
5. Cescon 2006 Cescon M, Grazi GL, Grassi A, Ravaioli M, Vetrone G, Ercolani G, et al. Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study. Liver Transplantation 2006;12(4):628-35.
6. Chalasani 2005 Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41(2):289-98.
7. Corno 2006 Corno V, Colledan M, Dezza MC, Guizzetti M, Lucianetti A, Maldini G, et al. Extended right split liver graft for primary transplantation in children and adults. Transplantation International 2006;19(6):492-9.
8. DeMets 1987 DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
9. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
10. Eason 2001 Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplantation 2001;7(8):693-7.
11. Egger 1997 Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
12. Gluud 2006 Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER.
13. Gurusamy 2007 Gurusamy KS, Samraj K, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. (Protocol) Cochrane Database of Systematic Reviews 2007:Issue 4.
14. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
15. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
16. Jain 2002 Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transplantation 2002;8(1):40-6.
17. Kamath 2001 Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-70.
18. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
19. Koneru 2005 Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, et al. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transplantation 2005;11(2):196-202.
20. Lim 2006 Lim SG, Wai CT, Da Costa M, Sutedja DS, Lee YM, Lee KH, et al. Referral patterns and waiting times for liver transplantation in Singapore. Singapore Medical Journal 2006;47(7):599-603.
21. Macaskill 2001 Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
22. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
23. Newell 1992 Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
24. NHS UK Transplant NHS UK Transplant - Annual Report 2003-2004. http://www.uktransplant.org.uk/ukt/about_us/annual_report/ archive_annual_reports/ann_report_2003_2004.pdf (accessed 14 February 2007).
25. OPTN/SRTR 2005 The Organ Procurement and Transplant Network/ Scientific Registry of Transplant Recipients 2005 Annual Report. http://www.ustransplant.org/annual_reports/current/905_li.pdf (accessed 14 February 2007).
26. RevMan 2003 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
27. Royle 2003 Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
28. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
29. Shiffman 2006 Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, et al. Liver and intestine transplantation in the United States, 1995-2004. American Journal of Transplantation 2006;6(5 Pt 2):1170-87.
30. Singh 1998 Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998;65(1):82-6.
31. Sugo 2003 Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, et al. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surgery Today 2003;33(6):421-5.
32. Sweeting 2004 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75.